Genomic Health' Oncotype DX Recurrence Score shows positive predictive results Genomic Health announced positive results of a large study that demonstrates the Oncotype DX Recurrence Score result to be a robust predictor of distant recurrence, disease-free survival, and overall survival in women with node-positive breast cancer who were treated with anthracycline-containing chemotherapy regimens. This study analyzes tumor samples from 1,065 hormone-positive, node-positive breast cancer patients who were treated with anthracycline-containing chemotherapy as part of the NSABP B-28 trial.
News For GHDX From The Last 14 Days
Check below for free stories on GHDX the last two weeks.
Subscribe for More Information